A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone

ABSTRACT: The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic against Enterococcus faecalis based on in vitro tests and the rabbit endocarditis model, however, in vitro assays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacte...

Full description

Autores:
Jiménez Toro, Ivone Eliana
Rodríguez Jaramillo, Carlos Andrés
Zuluaga Salazar, Andrés Felipe
Vesga Meneses, Omar
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/43307
Acceso en línea:
https://hdl.handle.net/10495/43307
Palabra clave:
Ampicilina
Ampicillin
Ceftriaxona
Ceftriaxone
Quimioterapia
Drug Therapy
Endocarditis
Enterococcus faecalis
Infecciones por Bacterias Grampositivas
Gram-Positive Bacterial Infections
Modelos Animales de Enfermedad
Disease Models, Animal
Quimioterapia Combinada
Drug Therapy, Combination
Endocarditis Bacteriana
Endocarditis, Bacterial
https://id.nlm.nih.gov/mesh/D000667
https://id.nlm.nih.gov/mesh/D002443
https://id.nlm.nih.gov/mesh/D004358
https://id.nlm.nih.gov/mesh/D004696
https://id.nlm.nih.gov/mesh/D013293
https://id.nlm.nih.gov/mesh/D016908
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D004359
https://id.nlm.nih.gov/mesh/D004697
Rights
openAccess
License
https://creativecommons.org/licenses/by/4.0/
id UDEA2_81e9ce0e562e035d01741034d492d63d
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/43307
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
title A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
spellingShingle A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
Ampicilina
Ampicillin
Ceftriaxona
Ceftriaxone
Quimioterapia
Drug Therapy
Endocarditis
Enterococcus faecalis
Infecciones por Bacterias Grampositivas
Gram-Positive Bacterial Infections
Modelos Animales de Enfermedad
Disease Models, Animal
Quimioterapia Combinada
Drug Therapy, Combination
Endocarditis Bacteriana
Endocarditis, Bacterial
https://id.nlm.nih.gov/mesh/D000667
https://id.nlm.nih.gov/mesh/D002443
https://id.nlm.nih.gov/mesh/D004358
https://id.nlm.nih.gov/mesh/D004696
https://id.nlm.nih.gov/mesh/D013293
https://id.nlm.nih.gov/mesh/D016908
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D004359
https://id.nlm.nih.gov/mesh/D004697
title_short A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
title_full A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
title_fullStr A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
title_full_unstemmed A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
title_sort A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
dc.creator.fl_str_mv Jiménez Toro, Ivone Eliana
Rodríguez Jaramillo, Carlos Andrés
Zuluaga Salazar, Andrés Felipe
Vesga Meneses, Omar
dc.contributor.author.none.fl_str_mv Jiménez Toro, Ivone Eliana
Rodríguez Jaramillo, Carlos Andrés
Zuluaga Salazar, Andrés Felipe
Vesga Meneses, Omar
dc.contributor.researchgroup.spa.fl_str_mv GRIPE: Grupo Investigador de Problemas en Enfermedades Infecciosas
dc.subject.decs.none.fl_str_mv Ampicilina
Ampicillin
Ceftriaxona
Ceftriaxone
Quimioterapia
Drug Therapy
Endocarditis
Enterococcus faecalis
Infecciones por Bacterias Grampositivas
Gram-Positive Bacterial Infections
Modelos Animales de Enfermedad
Disease Models, Animal
Quimioterapia Combinada
Drug Therapy, Combination
Endocarditis Bacteriana
Endocarditis, Bacterial
topic Ampicilina
Ampicillin
Ceftriaxona
Ceftriaxone
Quimioterapia
Drug Therapy
Endocarditis
Enterococcus faecalis
Infecciones por Bacterias Grampositivas
Gram-Positive Bacterial Infections
Modelos Animales de Enfermedad
Disease Models, Animal
Quimioterapia Combinada
Drug Therapy, Combination
Endocarditis Bacteriana
Endocarditis, Bacterial
https://id.nlm.nih.gov/mesh/D000667
https://id.nlm.nih.gov/mesh/D002443
https://id.nlm.nih.gov/mesh/D004358
https://id.nlm.nih.gov/mesh/D004696
https://id.nlm.nih.gov/mesh/D013293
https://id.nlm.nih.gov/mesh/D016908
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D004359
https://id.nlm.nih.gov/mesh/D004697
dc.subject.meshuri.none.fl_str_mv https://id.nlm.nih.gov/mesh/D000667
https://id.nlm.nih.gov/mesh/D002443
https://id.nlm.nih.gov/mesh/D004358
https://id.nlm.nih.gov/mesh/D004696
https://id.nlm.nih.gov/mesh/D013293
https://id.nlm.nih.gov/mesh/D016908
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D004359
https://id.nlm.nih.gov/mesh/D004697
description ABSTRACT: The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic against Enterococcus faecalis based on in vitro tests and the rabbit endocarditis model, however, in vitro assays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacterial growth, high variability, and the use of point dose-effect estimations, that may lead to inaccurate assessment of antibiotic combinations and hinder optimal translation. Here, we tested AMP+CRO against two strains of E. faecalis and one of E. faecium in an optimized mouse thigh infection model that yields high bacterial growth and allows to define the complete dose-response relationship. By fitting Hill’s sigmoid model and estimating the parameters maximal effect (Emax) and effective dose 50 (ED50), the following interactions were defined: synergism (Emax increase ≥2 log10 CFU/g), antagonism (Emax reduction ≥1 log10 CFU/g) and potentiation (ED50 reduction ≥50% without changes in Emax). AMP monotherapy was effective against the three strains, yielding valid dose-response curves in terms of dose and the index fT>MIC. CRO monotherapy showed no effect. The combination AMP+CRO against E. faecalis led to potentiation (59–81% ED50 reduction) and not synergism (no changes in Emax). Against E. faecium, the combination was indifferent. The optimized mouse infection model allowed to obtain the complete dose-response curve of AMP+CRO and to define its interaction based on pharmacodynamic parameter changes. Integrating these results with the pharmacokinetics will allow to derive the PK/PD index bound to the activity of the combination, essential for proper translation to the clinic.
publishDate 2020
dc.date.issued.none.fl_str_mv 2020
dc.date.accessioned.none.fl_str_mv 2024-11-08T20:25:41Z
dc.date.available.none.fl_str_mv 2024-11-08T20:25:41Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Jiménez-Toro I, Rodríguez CA, Zuluaga AF, Otalvaro JD, Vesga O. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS One. 2020 Dec 8;15(12):e0243365. doi: 10.1371/journal.pone.0243365.
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/43307
dc.identifier.doi.none.fl_str_mv 10.1371/journal.pone.0243365
dc.identifier.eissn.none.fl_str_mv 1932-6203
identifier_str_mv Jiménez-Toro I, Rodríguez CA, Zuluaga AF, Otalvaro JD, Vesga O. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS One. 2020 Dec 8;15(12):e0243365. doi: 10.1371/journal.pone.0243365.
10.1371/journal.pone.0243365
1932-6203
url https://hdl.handle.net/10495/43307
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv PLoS ONE.
dc.relation.citationendpage.spa.fl_str_mv 15
dc.relation.citationissue.spa.fl_str_mv 12
dc.relation.citationstartpage.spa.fl_str_mv 1
dc.relation.citationvolume.spa.fl_str_mv 15
dc.relation.ispartofjournal.spa.fl_str_mv PLoS ONE.
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by/4.0/
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/2.5/co/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
http://creativecommons.org/licenses/by/2.5/co/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 15 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Public Library of Science
dc.publisher.place.spa.fl_str_mv San Francisco, Estados Unidos
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/1c4c9157-7dac-4099-a528-54d4a84e917c/download
https://bibliotecadigital.udea.edu.co/bitstreams/a2c8712e-2eea-474c-b917-35e807a88a10/download
https://bibliotecadigital.udea.edu.co/bitstreams/2d8318ef-62a5-459c-9349-55ef788c1c6c/download
https://bibliotecadigital.udea.edu.co/bitstreams/b0990c00-6f07-4ad9-a217-fc9cfaab52b2/download
https://bibliotecadigital.udea.edu.co/bitstreams/17dada8f-3067-4257-8fba-10283378424a/download
bitstream.checksum.fl_str_mv 9118f94cce88d72cb3f099b9db8b2181
1646d1f6b96dbbbc38035efc9239ac9c
8a4605be74aa9ea9d79846c1fba20a33
c83f030b0b465382481ad332daf4f335
d9fb2a2e94d81c4b278efef94ed586df
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052594531663872
spelling Jiménez Toro, Ivone ElianaRodríguez Jaramillo, Carlos AndrésZuluaga Salazar, Andrés FelipeVesga Meneses, OmarGRIPE: Grupo Investigador de Problemas en Enfermedades Infecciosas2024-11-08T20:25:41Z2024-11-08T20:25:41Z2020Jiménez-Toro I, Rodríguez CA, Zuluaga AF, Otalvaro JD, Vesga O. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS One. 2020 Dec 8;15(12):e0243365. doi: 10.1371/journal.pone.0243365.https://hdl.handle.net/10495/4330710.1371/journal.pone.02433651932-6203ABSTRACT: The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic against Enterococcus faecalis based on in vitro tests and the rabbit endocarditis model, however, in vitro assays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacterial growth, high variability, and the use of point dose-effect estimations, that may lead to inaccurate assessment of antibiotic combinations and hinder optimal translation. Here, we tested AMP+CRO against two strains of E. faecalis and one of E. faecium in an optimized mouse thigh infection model that yields high bacterial growth and allows to define the complete dose-response relationship. By fitting Hill’s sigmoid model and estimating the parameters maximal effect (Emax) and effective dose 50 (ED50), the following interactions were defined: synergism (Emax increase ≥2 log10 CFU/g), antagonism (Emax reduction ≥1 log10 CFU/g) and potentiation (ED50 reduction ≥50% without changes in Emax). AMP monotherapy was effective against the three strains, yielding valid dose-response curves in terms of dose and the index fT>MIC. CRO monotherapy showed no effect. The combination AMP+CRO against E. faecalis led to potentiation (59–81% ED50 reduction) and not synergism (no changes in Emax). Against E. faecium, the combination was indifferent. The optimized mouse infection model allowed to obtain the complete dose-response curve of AMP+CRO and to define its interaction based on pharmacodynamic parameter changes. Integrating these results with the pharmacokinetics will allow to derive the PK/PD index bound to the activity of the combination, essential for proper translation to the clinic.Colombia. Ministerio de Ciencia, Tecnología e Innovación - MinCienciasCOL000574415 páginasapplication/pdfengPublic Library of ScienceSan Francisco, Estados Unidoshttps://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxoneArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAmpicilinaAmpicillinCeftriaxonaCeftriaxoneQuimioterapiaDrug TherapyEndocarditisEnterococcus faecalisInfecciones por Bacterias GrampositivasGram-Positive Bacterial InfectionsModelos Animales de EnfermedadDisease Models, AnimalQuimioterapia CombinadaDrug Therapy, CombinationEndocarditis BacterianaEndocarditis, Bacterialhttps://id.nlm.nih.gov/mesh/D000667https://id.nlm.nih.gov/mesh/D002443https://id.nlm.nih.gov/mesh/D004358https://id.nlm.nih.gov/mesh/D004696https://id.nlm.nih.gov/mesh/D013293https://id.nlm.nih.gov/mesh/D016908https://id.nlm.nih.gov/mesh/D004195https://id.nlm.nih.gov/mesh/D004359https://id.nlm.nih.gov/mesh/D004697PLoS ONE.1512115PLoS ONE.MinCiencias 111571149738RoR:03fd5ne08PublicationORIGINALJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdfJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdfArtículo de investigaciónapplication/pdf2092353https://bibliotecadigital.udea.edu.co/bitstreams/1c4c9157-7dac-4099-a528-54d4a84e917c/download9118f94cce88d72cb3f099b9db8b2181MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/a2c8712e-2eea-474c-b917-35e807a88a10/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/2d8318ef-62a5-459c-9349-55ef788c1c6c/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdf.txtJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdf.txtExtracted texttext/plain57903https://bibliotecadigital.udea.edu.co/bitstreams/b0990c00-6f07-4ad9-a217-fc9cfaab52b2/downloadc83f030b0b465382481ad332daf4f335MD54falseAnonymousREADTHUMBNAILJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdf.jpgJimenezIvone_2020_Application_Ampicillin_Ceftriaxone.pdf.jpgGenerated Thumbnailimage/jpeg16066https://bibliotecadigital.udea.edu.co/bitstreams/17dada8f-3067-4257-8fba-10283378424a/downloadd9fb2a2e94d81c4b278efef94ed586dfMD55falseAnonymousREAD10495/43307oai:bibliotecadigital.udea.edu.co:10495/433072025-03-27 00:47:29.665https://creativecommons.org/licenses/by/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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